Valuation: Omeros Corporation

Market Cap 1.17B 1.05B 970M 881M 1.65B 111B 1.68B 11.62B 4.56B 58.1B 4.4B 4.31B 186B P/E 2026 *
17.9x
P/E 2027 * 15.3x
Enterprise Value 1.17B 1.05B 970M 881M 1.65B 111B 1.68B 11.62B 4.56B 58.1B 4.4B 4.31B 186B EV / Sales 2026 *
9.2x
EV / Sales 2027 * 5.3x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day+0.93%
1 week-17.55%
Current month-14.13%
1 month-8.51%
3 months+68.73%
6 months+21.65%
Current year-4.80%
1 week 15.84
Extreme 15.845
19.78
1 month 15.84
Extreme 15.845
21.24
Current year 6.7
Extreme 6.7023
21.24
1 year 6.24
Extreme 6.24
21.24
3 years 1.05
Extreme 1.05
21.24
5 years 0.92
Extreme 0.92
21.24
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 15/06/1994
Director of Finance/CFO 62 29/06/2024
Chief Tech/Sci/R&D Officer 70 31/10/2019
Director TitleAgeSince
Chairman 67 15/06/1994
Director/Board Member 86 31/12/1994
Director/Board Member 72 31/12/1994
Date Insider Type Main position Quantity % Market Cap. Importance
23/09/26 Exercice

Chief Financial Officer

30,000 0.0414%
31/08/26 Exercice

General Counsel

75,000 0.1036%
27/08/26 Exercice

Director

30,000 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%-17.55%+101.73%+1,063.70% 1.17B
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+7.17%+10.77%+77.89% 51.2B
+0.30%+0.19%+2.53%+56.14% 51.19B
-0.38%+2.31%+29.98%+40.71% 43.93B
+0.30%+4.43%+16.99%+120.94% 41.96B
+2.35%-4.01%+236.69%+497.21% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+3.97%+21.34%+22.33% 22.5B
Average +0.94%-1.70%+52.77%+200.78% 37.35B
Weighted average by Cap. +0.97%-0.02%+46.20%+109.36%

Financials

2026 *2027 *
Net sales 128M 114M 105M 95.82M 180M 12.1B 183M 1.26B 496M 6.32B 478M 468M 20.22B 221M 197M 183M 166M 312M 21.01B 317M 2.19B 862M 10.97B 830M 813M 35.09B
Net income 64.97M 57.94M 53.71M 48.82M 91.64M 6.17B 93.06M 644M 253M 3.22B 244M 239M 10.3B 84.8M 75.63M 70.11M 63.73M 120M 8.05B 121M 840M 330M 4.2B 318M 311M 13.45B
Net Debt - -
Projected Income Statement - Annual - Omeros Corporation
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
19/10/26 US$16.35 +0.93% 1,382,868
16/10/26 US$16.20 -13.78% 3,965,862
15/10/26 US$18.79 +1.95% 931,367
14/10/26 US$18.43 -2.38% 905,106
13/10/26 US$18.88 -3.82% 994,056
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Omeros Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.34USD
Average target price
27.50USD
Spread / Average Target
+68.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Omeros Corporation
  1. Stock Market
  2. Stocks
  3. OMER Stock